Barb Rohrer, Ph.D.
Endowed Chair, Gene & Pharmaceutical Treatment of Retinal Degenerative Disease, Medical University of South Carolina
Bärbel (Barb) Rohrer, Ph.D. is a graduate of the University of Tübingen, Tübingen, Germany, with a diploma in Biology/Cybernetics. Dr. Rohrer received her doctorate degree from the University of Calgary in Visual Neuroscience, where, in William K. Stell’s laboratory, she was the first to examine the role of neurotransmitters and local growth factors within the eye in the control of myopia. She then completed postdoctoral studies in Neuroscience at the University of California at San Francisco with Louis F. Reichardt, establishing the groundwork for her studies on neuroprotective agents in retina development and disease. Dr. Rohrer’s efforts are focused in particular on age-related macular degeneration (AMD) and retinitis pigmentosa (RP).
Aubrey de Grey Ph.D.
Chief Science Officer at SENS Foundation
Dr. de Grey is the biomedical gerontologist who researched the idea for and founded SENS Research Foundation. He received his BA in Computer Science and Ph.D. in Biology from the University of Cambridge in 1985 and 2000, respectively. Dr. de Grey is Editor-in-Chief of Rejuvenation Research, is a Fellow of both the Gerontological Society of America and the American Aging Association, and sits on the editorial and scientific advisory boards of numerous journals and organizations. Click here to download a copy of Dr. de Grey’s CV.
Robert Doyle Ph.D.
Professor of Chemistry at Syracuse University
Professor Robert Doyle holds a PhD in Chemistry from Trinity College, Dublin, Ireland (2002). He was a RSC fellow at the Australian National University (2002-2003) and a Rudolph Anderson Foundation fellow while at Yale University (2003-2005). He is currently Professor at Chemistry at Syracuse University and Associate Professor of Medicine at SUNY, Upstate Medical University. He also holds an appointment at the Syracuse Veterans Affairs medical Center. He is currently funded by the NIH and several industrial partners and was named CNY University Technology Educator of the year in 2013.
Doug Hagrman, Ph.D.
Assistant Professor of Chemistry at OCC
Dr. Doug Hagrman is a synthetic and analytical chemist. He currently holds the position of Assistant Professor of Chemistry at Onondaga Community College. Doug obtained a Ph.D. in chemistry from Syracuse University, during which time he received several distinctions including the SU Outstanding Teaching Assistant Award, the SU Chemistry Department William D. Johnson Award for an Outstanding Teaching Assistant, and the Pauling Poster Prize for outstanding student research poster. Following his degree, he completed a post-doctoral fellowship involving research with Cornell’s High Energy Synchrotron Source (CHESS) and Syracuse University, doing anomalous small angle X-ray scattering experiments on zeolites incorporated with platinum. Doug subsequently completed a second post-doctoral fellowship involving research on platinum chemotherapy drugs at SUNY Upstate in the Department of Pediatric Oncology.
Igor Bussel MD, MS, MHA
Dr. Bussel is an aspiring clinician-scientist in the field of ophthalmology focused on translating regenerative discoveries to patient application. He graduated from UCI with a BS in Biological Sciences and distinction for excellence in research on evolutionary genetics of aging. Following, he joined the UCI Department of Pharmaceutical Sciences as a research scientist to develop and validate methods for anti-aging pharmacology. He received an MD/MHA from the Chicago Medical School at RFUMS. Dr. Bussel recently completed a Doris Duke Clinical Research Fellowship in the ophthalmic imaging research laboratory in the Department of Ophthalmology at the University of Pittsburgh. He has extensive research experience in clinical trials, diagnostic imaging, surgical outcomes, dietary factors, and stem cell therapies in ophthalmology. He is currently a resident physician in the Department of Ophthalmology at the University of Pittsburgh and the UPMC Eye Center.
Brandon Clair MD
Dr. Clair is an investigator and resident physician affiliated with the Department of Medicine at the University of Maryland, the Department of Ophthalmology at the University at Buffalo, and the Ross Eye Institute. His scientific pursuits span Ophthalmology, Orthopedic Surgery, Otolaryngology, and Medicine. His latest endeavors involve the study of cell and metabolically mediated autophagy in autoimmune cell lines, metabolic augmentation of retinal cellular metabolism, statistical analyses of trends within medical economic data, and evaluation of surgical approaches in orbital tumor resections. He holds an MD from SUNY Upstate Medical University and a BA from Hamilton College.
Todd Wallach MBA, MS, MB, BSc
Life Science Executive
Mr. Wallach has 30+ years of experience in the life sciences, having built companies with total market cap. of >$1B, managed P&Ls of >$50M and raised >$75M in capital. He is currently CEO of Evogen Inc., and was previously an officer and member of the founding management at Molecular Detection Inc. and Aton Pharma, Inc. (acq. by Valeant Pharm.). Prior to Aton Pharma, Mr. Wallach was VP of Finance and Operations at Acuity Pharma (acq. by Opko, NASDAQ: OPK), a macular degeneration company. Mr. Wallach is a former member of the IRB for Clinical Trials at UPenn. He holds an MSE from UPenn, an MB from UPenn, an MBA from Rider University and B.S. from Purdue University.
Life Science Executive
Rob is an entrepreneurial business executive. In his most recent role, he worked with Provepharm SAS as VP of Business Development and Operations to create partnerships among companies using and seeking to develop indications for methylene blue. From 2008 – 2012, Rob founded and operated AzGardaBio, a start-up which licensed an oncolytic virus from Yale University for the purpose of developing target indications in glioblastoma, lung and pancreatic cancers. Earlier, Rob served as VP of Business and Project Development with Bioenvision. During his tenure, Rob helped shape the company from a virtual business in 2001 to a commercial operation with sales professionals and an EMeA approved product in the European Union by 2006. This work included drug and technology out-licensing of 3 drugs/technologies and development of new formulations. As a public face of the company, Rob was an active presenter various conferences and meetings. His efforts helped the company raise over $100M, followed by a later exit to Genzyme for $345 million. Previously, he led a 100% growth during his management and marketing role at Hoechst Roussel.
Maximus Peto MBA, BBA
Project Manager, Research Analyst
Mr. Peto has a diverse set of experiences and education focused on biotechnology research and entrepreneurship, with an emphasis on human aging. He has extensive experience studying the scientific literature on human aging biology, as well as >6 years of biochemical lab experience. His topical foci have included energy metabolism, insulin resistance, A2E, lipofuscin, macular degeneration, and recombinant protein manufacturing. He also has a background in finance and accounting as a cost and financial statement accountant. Max is currently a Project Manager for the Life Extension Foundation and a Research Analyst for SENS Research Foundation.